Tenax Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Tenax Therapeutics, Inc.'s free cash flow has decreased 141.71% from $-14.81M last year to $-35.80M, signaling decreasing performance

Tenax Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Tenax Therapeutics, Inc. has insufficient data to evaluate this check.

Tenax Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Tenax Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Tenax Therapeutics, Inc. has insufficient data to evaluate this check.

Tenax Therapeutics, Inc.'s short-term assets of $104.23M exceed its short-term liabilities of $7.16M

Tenax Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Tenax Therapeutics, Inc.'s return on equity of -56.32%, is lower than 15.00%, indicating bad performance

Tenax Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Tenax Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Tenax Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Tenax Therapeutics, Inc. has negative free cash flow, indicating cash burn

Tenax Therapeutics, Inc.'s yearly earnings has decreased 198.82% since last year from $-17.60M to $-52.60M, signaling decreasing performance

Tenax Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -53.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Tenax Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Tenax Therapeutics, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Tenax Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Tenax Therapeutics, Inc. has insufficient data to evaluate this check.

Tenax Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tenax Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Tenax Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Tenax Therapeutics, Inc. has insufficient data to evaluate this check.

Tenax Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tenax Therapeutics, Inc. has a price-to-book ratio of 5.30x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Tenax Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue